Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more
Market Cap & Net Worth: Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (NASDAQ:ANIX) has a market capitalization of $96.47 Million ($96.47 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18628 globally and #6917 in its home market, demonstrating a 1.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anixa Biosciences Inc's stock price $2.89 by its total outstanding shares 33379505 (33.38 Million).
Anixa Biosciences Inc Market Cap History: 2015 to 2026
Anixa Biosciences Inc's market capitalization history from 2015 to 2026. Data shows change from $100.47 Million to $96.47 Million (-3.10% CAGR).
Index Memberships
Anixa Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #509 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1716 of 3165 |
Weight: Anixa Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anixa Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anixa Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
616.73x
Anixa Biosciences Inc's market cap is 616.73 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $180.25 Million | $300.00K | -$5.02 Million | 600.83x | N/A |
| 2017 | $78.78 Million | $362.50K | -$5.01 Million | 217.31x | N/A |
| 2018 | $131.52 Million | $1.11 Million | -$14.00 Million | 118.22x | N/A |
| 2019 | $109.48 Million | $250.00K | -$11.65 Million | 437.94x | N/A |
| 2021 | $99.14 Million | $512.00K | -$12.95 Million | 193.63x | N/A |
| 2022 | $141.86 Million | $2.47 Billion | -$13.60 Million | 0.06x | N/A |
| 2023 | $129.51 Million | $210.00K | -$9.81 Million | 616.73x | N/A |
Competitor Companies of ANIX by Market Capitalization
Companies near Anixa Biosciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Anixa Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Anixa Biosciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Anixa Biosciences Inc's market cap moved from $100.47 Million to $ 96.47 Million, with a yearly change of -3.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $96.47 Million | -7.37% |
| 2025 | $104.14 Million | +34.48% |
| 2024 | $77.44 Million | -40.21% |
| 2023 | $129.51 Million | -8.71% |
| 2022 | $141.86 Million | +43.10% |
| 2021 | $99.14 Million | -3.26% |
| 2020 | $102.48 Million | -6.40% |
| 2019 | $109.48 Million | -16.75% |
| 2018 | $131.52 Million | +66.95% |
| 2017 | $78.78 Million | -56.30% |
| 2016 | $180.25 Million | +79.40% |
| 2015 | $100.47 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Anixa Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $96.47 Million USD |
| MoneyControl | $96.47 Million USD |
| MarketWatch | $96.47 Million USD |
| marketcap.company | $96.47 Million USD |
| Reuters | $96.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.